{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:07:08Z","timestamp":1793830028439,"version":"4.6.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000550","name":"British Geriatrics Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013703","name":"Royal Osteoporosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jbo.2020.100311","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T10:42:42Z","timestamp":1596364962000},"page":"100311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group"],"prefix":"10.1016","volume":"25","author":[{"given":"Janet E.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Handforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet E.","family":"Compston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-3053","authenticated-orcid":false,"given":"William","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-9268","authenticated-orcid":false,"given":"Peter","family":"Selby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8570-5100","authenticated-orcid":false,"given":"Lawrence","family":"Drudge-Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7122-2650","authenticated-orcid":false,"given":"Jennifer S.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4790-0095","authenticated-orcid":false,"given":"Caroline","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona J.","family":"Collinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2020.100311_b0005","unstructured":"Cancer research UK mortality statistics. Available from: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer\/mortality#heading-Zero."},{"key":"10.1016\/j.jbo.2020.100311_b0010","unstructured":"Cancer Research UK. Cancer statistics. 2013 Available from: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer\/incidence#heading-One."},{"key":"10.1016\/j.jbo.2020.100311_b0015","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.ejca.2012.01.035","article-title":"Incidence of fractures causing hospitalisation in prostate cancer patients: Results from the population-based PCBaSe Sweden","volume":"48","author":"Thorstenson","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"10.1016\/j.jbo.2020.100311_b0020","article-title":"Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management","volume":"6","author":"D'Oronzo","year":"2018","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0030","unstructured":"National Institute for Health and Clinical Excellence (NICE). Prostate cancer: diagnosis and management. Clinical guideline 175. London, UK: 2014. Available from: https:\/\/www.nice.org.uk\/guidance\/cg175."},{"key":"10.1016\/j.jbo.2020.100311_b0035","unstructured":"Mottet N, Bellmunt J, Briers E, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. 2016. Available from: https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-Prostate-Cancer-2016.pdf."},{"key":"10.1016\/j.jbo.2020.100311_b0040","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario Guideline","volume":"38","author":"Saylor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0045","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Version 2.2020. Page 46."},{"key":"10.1016\/j.jbo.2020.100311_b0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","author":"Denham","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0055","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0060","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92\u201302","volume":"21","author":"Hanks","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0065","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus Continuous Androgen Deprivation in Prostate Cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0070","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2147\/CMAR.S164856","article-title":"Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach","volume":"10","author":"Bonfill","year":"2018","journal-title":"Cancer Manage. Res."},{"key":"10.1016\/j.jbo.2020.100311_b0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/pcan.2009.50","article-title":"Bone health and prostate cancer","volume":"13","author":"Saylor","year":"2010","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.jbo.2020.100311_b0080","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1464-410X.2003.04471.x","article-title":"Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation","volume":"92","author":"Hussain","year":"2003","journal-title":"BJU Int."},{"key":"10.1016\/j.jbo.2020.100311_b0085","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2020.100311_b0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2020.100311_b0095","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bone.2019.06.005","article-title":"Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy","volume":"127","author":"Dalla Via","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2020.100311_b0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.2013.49.5523","article-title":"Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: A systematic review","volume":"32","author":"Gardner","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0105","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2020.100311_b0110","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0115","unstructured":"National Institute for Health and Care Excellence. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. 2016. Available from: https:\/\/www.nice.org.uk\/terms-and-."},{"key":"10.1016\/j.jbo.2020.100311_b0120","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0125","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 5","key":"10.1016\/j.jbo.2020.100311_b0130","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"eUpdate 2017 \u2013 Cancer of the Prostate Treatment Recommendations: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Parker","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0135","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0140","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0150","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0155","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0165","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"issue":"15 suppl","key":"10.1016\/j.jbo.2020.100311_b0170","article-title":"Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC)","volume":"37","author":"Alonzi","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"15 suppl","key":"10.1016\/j.jbo.2020.100311_b0175","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1200\/JCO.2019.37.15_suppl.5007","article-title":"Decreased fracture rate by mandating bone protecting agents in the EORTC1333\/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone. Early results","volume":"37","author":"Tombal","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0180","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaci.2013.08.040","article-title":"Glucocorticoid-induced osteoporosis: An update on effects and management","volume":"132","author":"Buehring","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jbo.2020.100311_b0185","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2020.100311_b0190","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","article-title":"A reference standard for the description of osteoporosis","author":"Kanis","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2020.100311_b0195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","article-title":"Osteoporosis in the European Union: a compendium of country-specific reports","volume":"8","author":"Svedbom","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.jbo.2020.100311_b0200","unstructured":"National Osteoporosis Guideline Group. Osteoporosis Clinical guideline for prevention and treatment: Executive Summary. 2016. Available from: https:\/\/www.shef.ac.uk\/NOGG\/NOGG_Executive_Summary.pdf."},{"key":"10.1016\/j.jbo.2020.100311_b0205","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/MLR.0000000000000383","article-title":"The impact of a national clinician-led audit initiative on care and mortality after hip fracture in England","volume":"53","author":"Neuburger","year":"2015","journal-title":"Med. Care"},{"key":"10.1016\/j.jbo.2020.100311_b0210","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","article-title":"Meta-analysis: excess mortality after hip fracture among older women and men","volume":"152","author":"Haentjens","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0215","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/17530050903473147","article-title":"Biomarkers of bone turnover in oncology: applications in diagnosis and treatment","volume":"4","author":"Brown","year":"2010","journal-title":"Expert Opin. Med. Diagn."},{"key":"10.1016\/j.jbo.2020.100311_b0220","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1464-410X.2012.11777.x","article-title":"Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer","volume":"118","author":"Nadler","year":"2013","journal-title":"BJU Int."},{"key":"10.1016\/j.jbo.2020.100311_b0225","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00198-014-2997-6","article-title":"Bone health management in men undergoing ADT: examining enablers and barriers to care","volume":"26","author":"Damji","year":"2015","journal-title":"Osteoporos. Int."},{"issue":"4Supp","key":"10.1016\/j.jbo.2020.100311_b0230","first-page":"e290","article-title":"Educational needs of urologists on bone health in prostate cancer","volume":"185","author":"Ellsworth","year":"2011","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2020.100311_b0235","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/cncr.21047","article-title":"Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy","volume":"103","author":"Agarwal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2020.100311_b0240","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1002\/cncr.29406","article-title":"The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer","volume":"121","author":"Buffart","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2020.100311_b0245","unstructured":"https:\/\/www.nice.org.uk\/search?q=NG131."},{"key":"10.1016\/j.jbo.2020.100311_b0250","unstructured":"https:\/\/theros.org.uk\/."},{"issue":"Suppl 3","key":"10.1016\/j.jbo.2020.100311_b0255","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0260","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","article-title":"Osteoporosis in the European Union: a compendium of country-specific reports","volume":"8","author":"Svedbom","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.jbo.2020.100311_b0265","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1464-410X.2006.06695.x","article-title":"The relationship between daily calcium intake and bone mineral density in men with prostate cancer","volume":"99","author":"Planas","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.jbo.2020.100311_b0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jbo.2020.100311_b0275","unstructured":"National Osteoporosis Guideline Group. NOGG 2017: Clinical guideline for the prevention and treatment of osteoporosis 2017. Available from: https:\/\/www.sheffield.ac.uk\/NOGG\/NOGGGuideline 2017.pdf."},{"key":"10.1016\/j.jbo.2020.100311_b0280","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0285","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2020.100311_b0290","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2020.100311_b0295","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.eururo.2005.01.012","article-title":"Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with neridronate","volume":"47","author":"Magno","year":"2005","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2020.100311_b0300","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2020.100311_b0305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1464-410X.2007.06853.x","article-title":"Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid","volume":"100","author":"Ryan","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.jbo.2020.100311_b0310","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbo.2020.100311_b0315","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0320","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0325","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","article-title":"Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy","volume":"182","author":"Bhoopalam","year":"2009","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2020.100311_b0330","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jbo.2020.100311_b0335","first-page":"195","article-title":"Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study","volume":"13","author":"Doria","year":"2016","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"10.1016\/j.jbo.2020.100311_b0340","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2012.11.007","article-title":"Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy","volume":"85","author":"Choo","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jbo.2020.100311_b0345","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","article-title":"A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leupr","volume":"63","author":"Klotz","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2020.100311_b0350","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/pcan.2011.4","article-title":"Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"15","author":"Serpa Neto","year":"2012","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.jbo.2020.100311_b0355","unstructured":"M.R. Smith, F. Saad, R. Coleman, et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. [cited 2018 Sep 21]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3671878\/pdf\/nihms472298.pdf."},{"key":"10.1016\/j.jbo.2020.100311_b0360","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2020.100311_b0365","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2020.100311_b0370","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00198-017-4134-9","article-title":"Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway","volume":"28","author":"Hoff","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jbo.2020.100311_b0375","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00198-015-3295-7","article-title":"FRAX predicts incident falls in elderly men: findings from MrOs Sweden","volume":"27","author":"Harvey","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jbo.2020.100311_b0380","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00198-017-3929-z","article-title":"The association between sarcopenia and functional outcomes among older patients with hip fracture undergoing in-hospital rehabilitation","volume":"28","author":"Landi","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"15S","key":"10.1016\/j.jbo.2020.100311_b0385","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1200\/jco.2009.27.15_suppl.9517","article-title":"Use of age and BMD to predict fracture risk in men on androgen deprivation therapy","volume":"27","author":"Lin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2020.100311_b0390","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.bone.2008.05.003","article-title":"Incidence and risk factors for low trauma fractures in men with prostate cancer","volume":"43","author":"Ahlborg","year":"2008","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.jbo.2020.100311_b0395","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-016-0278-z","article-title":"A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation","volume":"11","author":"Kanis","year":"2016","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.jbo.2020.100311_b0400","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.maturitas.2008.11.022","article-title":"Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK","volume":"62","author":"Compston","year":"2009","journal-title":"Maturitas"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742030066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742030066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:18:15Z","timestamp":1761941895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221213742030066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":80,"alternative-id":["S221213742030066X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2020.100311","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2020.100311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100311"}}